ProQR (PRQR)
NASDAQ:PRQR
Want to see PRQR full AI Analyst Report?
PRQR Stock Chart & Stats
$1.99
-$0.10(-3.77%)
At close: 4:00 PM EST
$1.99
-$0.10(-3.77%)
Day’s Range― - ―
52-Week Range$1.33 - $3.10
Previous CloseN/A
Volume75.97K
Average Volume (3M)534.76K
Market Cap
$154.88M
Enterprise Value$75.28M
Total Cash (Recent Filing)$81.17M
Total Debt (Recent Filing)$13.70M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Jul 30, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding105,361,060
10 Day Avg. Volume796,312
30 Day Avg. Volume534,757
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.67
Price to Sales (P/S)11.85
P/FCF Ratio-3.50
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue5.60
Enterprise Value/Gross Profit6.24
Enterprise Value/Ebitda-1.73
Forecast
1Y Price Target
$8.20Price Target Upside312.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$20.65M
Bulls Say, Bears Say
Bulls Say
Axiomer Platform Expansion Via AI PartnershipThe strategic collaboration with Ginkgo and an AI advisory board represents a structural shift to high-throughput, AI-driven discovery. Access to Nebula and a partner equity stake aligns incentives, improving candidate throughput and lowering long-term R&D cycle risk while strengthening ProQR’s platform differentiation in RNA editing.
Advancing Lead Candidate AX-0810 Through ClinicProgressing AX-0810 through target-engagement readouts and planning Phase 2 in a defined indication materially de-risks the platform if clinical proof emerges. Moving into disease-focused trials and investigator-initiated pediatric studies builds durable clinical development momentum and credibility with partners and regulators.
Meaningful Cash Runway And Low Long-term DebtA multi-quarter runway into mid-2027 provides structural funding to advance multiple clinical programs without immediate refinancing. Combined with modest long-term debt, this supports sustained R&D execution and strategic optionality, reducing near-term liquidity pressure while clinical catalysts are pursued.
Bears Say
Declining Revenue TrendA sustained top-line decline undermines operating leverage and implies limited commercial traction or variability in collaboration revenue. With revenue contracting, high gross margins are less meaningful, and the company faces ongoing pressure to justify its cost base and fund development without predictable recurring revenue.
Large, Persistent Cash BurnConsistent negative operating and free cash flow indicates reliance on external capital to sustain R&D. This structural cash burn elevates dilution risk and constrains strategic flexibility; absent clinical value inflection, management will likely need to raise funds before key proofs, which can affect long-term ownership and program pacing.
Deep Operating Losses And Equity ErosionSevere negative margins and a large negative ROE reflect persistent unprofitability that is eroding shareholder equity. Over time this depletes balance-sheet resilience, limits leverage for partnerships or M&A, and increases dependency on capital markets—heightening long-term execution risk if clinical milestones slip.
ProQR News
PRQR FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $1.33 and its highest was $3.10 in the past 12 months.
What is ProQR’s market cap?
ProQR’s market cap is $154.88M.
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is Jul 30, 2026 which is in 57 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on May 12, 2026. The company reported -$0.151 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.012.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -0.14.
How many shares outstanding does ProQR have?
ProQR has 105,361,060 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -$0.151 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went down -0.621%.
Which hedge fund is a major shareholder of ProQR?
Currently, no hedge funds are holding shares in PRQR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProQR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.20 (312.06% Upside)
$8.20 (312.06% Upside)
Hedge Fund Trend
Increased
By 91.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.08%
12-Months-Change
Fundamentals
Return on Equity
-86.47%
Trailing 12-Months
Asset Growth
-30.36%
Trailing 12-Months
Company Description
ProQR
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
PRQR Stock 12 Month Forecast
Average Price Target
$8.20
▲(312.06% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.85% Mutual Funds
23.37% Other Institutional Investors
74.37% Public Companies and
Individual Investors